Sit 2022: Trametinib potest fieri nova regula curationis recurrentis, gradus serosi cancer ovarii ignobilis (Mekinist). Secundum studium inventionum in Februario 2022 editae exitus Lanceae, trametinib tam chemotherapy quam anti-estrogenis sicut tamoxifenum per circuitum 52 centesimis percutere, additis sex mensibus progressionis liberorum (tempus quo cancer non proficiebat) aegris superesset.
Anno 260 mulieres cum recurrentes tumores serosos ovarii, qui chemotherapy antea receperant, investigatores ex Civitatibus Foederatis et Regno Britanniae semel cottidiano orali trametinib ad unum quinque regulas curationis normas (sive medicamentum chemotherapy vel anti-estrogenium) comparaverunt. Cum participibus trametinib usitatis comparatur responsio ad therapiam post 15 menses quadruplum altiorem ostendit. Trametinib outperformed all other treatments, slow progressionem morborum 13 mensium (versus septem mensium ad curationi vexillum). Cutis temeraria, anaemia, pressura sanguinis alta, diarrhoea, et lassitudo quaedam sunt potentiae periculosae adversae effectus trametinib curationis.
Low-grade serous ovarian cancer is a difficult-to-treat invasive form of ovarian cancer marked by strong hormone receptor activation, genetic alterations, and poor chemotherapy response. Until now, the cancer toolbox lacked effective therapeutic options for patients with low-grade serous ovarian cancer. According to an editorial accompanying the report, 70% of these women will recur, with only 5% responding to further chemotherapy.
